Novo Nordisk A/S (NYSE:NVO) Shares Sold by Flputnam Investment Management Co.

Flputnam Investment Management Co. lessened its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 4.6% in the fourth quarter, HoldingsChannel reports. The fund owned 4,910 shares of the company’s stock after selling 235 shares during the period. Flputnam Investment Management Co.’s holdings in Novo Nordisk A/S were worth $508,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. Private Client Services LLC bought a new stake in shares of Novo Nordisk A/S in the 4th quarter worth $381,000. Keel Point LLC raised its stake in shares of Novo Nordisk A/S by 7.8% in the 4th quarter. Keel Point LLC now owns 6,724 shares of the company’s stock worth $696,000 after buying an additional 489 shares in the last quarter. Bison Wealth LLC raised its stake in shares of Novo Nordisk A/S by 27.1% in the 4th quarter. Bison Wealth LLC now owns 7,571 shares of the company’s stock worth $783,000 after buying an additional 1,613 shares in the last quarter. Hoxton Planning & Management LLC raised its stake in shares of Novo Nordisk A/S by 4.9% in the 4th quarter. Hoxton Planning & Management LLC now owns 3,632 shares of the company’s stock worth $376,000 after buying an additional 171 shares in the last quarter. Finally, Ballast Advisors LLC raised its stake in shares of Novo Nordisk A/S by 28.0% in the 4th quarter. Ballast Advisors LLC now owns 15,890 shares of the company’s stock worth $1,644,000 after buying an additional 3,478 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on NVO. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Monday, April 1st. BMO Capital Markets began coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective on the stock. UBS Group assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a “neutral” rating on the stock. Finally, Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price on the stock. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Stock Up 0.9 %

Shares of Novo Nordisk A/S stock opened at $124.55 on Thursday. The stock’s fifty day moving average is $126.28 and its 200-day moving average is $110.42. The firm has a market capitalization of $558.92 billion, a PE ratio of 46.04, a price-to-earnings-growth ratio of 2.06 and a beta of 0.41. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. Novo Nordisk A/S has a 12-month low of $75.56 and a 12-month high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.05. The firm had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. Equities analysts anticipate that Novo Nordisk A/S will post 3.33 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were given a dividend of $0.664 per share. This represents a yield of 0.9%. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date was Friday, March 22nd. Novo Nordisk A/S’s payout ratio is presently 49.17%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.